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Prognostic relevance of molecular subtypes
and master regulators in pancreatic ductal
adenocarcinoma
Rekin’s Janky1*†, Maria Mercedes Binda2†, Joke Allemeersch3, Anke Van den broeck2, Olivier Govaere4,
Johannes V. Swinnen5, Tania Roskams4, Stein Aerts1*† and Baki Topal2*†
Abstract
Background: Pancreatic cancer is poorly characterized at genetic and non-genetic levels. The current study evaluates
in a large cohort of patients the prognostic relevance of molecular subtypes and key transcription factors in pancreatic
ductal adenocarcinoma (PDAC).
Methods: We performed gene expression analysis of whole-tumor tissue obtained from 118 surgically resected PDAC
and 13 histologically normal pancreatic tissue samples. Cox regression models were used to study the effect on survival
of molecular subtypes and 16 clinicopathological prognostic factors. In order to better understand the biology of PDAC
we used iRegulon to identify transcription factors (TFs) as master regulators of PDAC and its subtypes.
Results: We confirmed the PDAssign gene signature as classifier of PDAC in molecular subtypes with prognostic
relevance. We found molecular subtypes, but not clinicopathological factors, as independent predictors of survival.
Regulatory network analysis predicted that HNF1A/B are among thousand TFs the top enriched master regulators of the
genes expressed in the normal pancreatic tissue compared to the PDAC regulatory network. On immunohistochemistry
staining of PDAC samples, we observed low expression of HNF1B in well differentiated towards no expression in poorly
differentiated PDAC samples. We predicted IRF/STAT, AP-1, and ETS-family members as key transcription factors in gene
signatures downstream of mutated KRAS.
Conclusions: PDAC can be classified in molecular subtypes that independently predict survival. HNF1A/B seem to be
good candidates as master regulators of pancreatic differentiation, which at the protein level loses its expression in
malignant ductal cells of the pancreas, suggesting its putative role as tumor suppressor in pancreatic cancer.
Trial registration: The study was registered at ClinicalTrials.gov under the number NCT01116791 (May 3, 2010).
Keywords: Pancreatic ductal adenocarcinoma, Molecular subtypes, Master regulators, HNF1A/B
Background
Pancreatic ductal adenocarcinoma (PDAC; also called
pancreatic cancer) is one of the most aggressive cancers,
associated with a poor prognosis [1]. The lack of early
diagnostic markers and efficient therapeutic modalities
for PDAC results in extremely poor prognosis. For
several decades, many efforts have been undertaken to
better understand the pathogenesis and biology of
PDAC, and to improve patient survival through early
diagnosis and various therapeutic strategies. However,
no substantial advances have been made to overcome its
lethal destiny. Today, adequate surgical resection is the
only chance for patients to be cured from PDAC, often
in combination with peri- or post-operative chemo(ra-
dio)therapy [2, 3]. Unfortunately, only selected patients
with localized disease are potential candidates for surgi-
cal management with curative intent. Even in the group
of surgically treated curable patients, the majority will
develop cancer recurrence and die within two years.
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Most patients with pancreatic cancer are not eligible for
surgery as they present in advanced stages with distant
organ metastases and/or locoregional extension. Sys-
temic chemotherapy is the standard of care for patients
with advanced inoperable PDAC, resulting in a median
survival of about 8 months [4].
As currently available clinicopathological classification
systems and treatment modalities fail to tailor patient
management or improve survival substantially, molecu-
lar subtyping of PDAC may help unravel its mechanisms
of carcinogenesis and progression, and help discover
efficient therapeutic molecules. The quest to identify
clinically relevant gene signatures of PDAC has been a
rough journey resulting in a wide range of often non-
reproducible or conflicting data. Recently, based on 27
microdissected surgical samples, three subtypes of
PDAC (classical, quasimesenchymal, and exocrine-like)
were identified and their gene signatures defined as
PDAssign. Despite its small sample size the study
presented a prognostic relevance for these subtypes [5].
The aim of our study was to evaluate the prognostic
relevance of molecular subtypes and identify key tran-
scription factors as master regulators in a large cohort of
PDAC patients. Hereto, in contrast to other studies, we
analyzed also several relevant clinicopathological vari-
ables that have proven to influence survival significantly.
Methods
Data collection
Between 1998 and 2010, tissue samples were collected,
after written informed consent, from patients who under-
went pancreatic resection for PDAC. Snap-frozen tissue
samples were stored in liquid nitrogen and/or at −80 °C in
RNALater (Qiagen) until further use. From the primary
tumor of 171 patients and from surrounding non-tumoral
pancreatic (control) tissue of 14 patients, total RNA was
extracted using the RNeasy Mini kit (Qiagen) according
the manufacturer’s instructions. Only samples with an
RNA integrity number (RIN) of >7.0 were used for further
analysis, i.e. 118 PDAC samples (male/female ratio: 65/53;
age: 32–87 years with median of 64 years) and 13 control
tissues (male/female ratio: 8/5; age: 51–78 years with
median of 67 years). Two pathologists confirmed PDAC
samples to contain at least 30 % cancer cells. Patients
with pre-operative radio- or chemotherapy were ex-
cluded from the study.
Microarray hybridization
RNA concentration and purity were determined spectro-
photometrically using the Nanodrop ND-1000 (Nanodrop
Technologies) and RNA integrity was assessed using a
Bioanalyser 2100 (Agilent). Per sample, an amount of
100 ng of total RNA spiked with bacterial RNA transcript
positive controls (Affymetrix) was amplified and labeled
using the GeneChip 3′ IVT express kit (Affymetrix). All
steps were carried out according to the manufacturers
protocol (Affymetrix). A mixture of purified and fragmen-
ted biotinylated amplified RNA (aRNA) and hybridisation
controls (Affymetrix) was hybridized on Affymetrix
Human Genome U219 Array Plate followed by staining
and washing in the GeneTitan® Instrument (Affymetrix)
according to the manufacturer’s procedures. To assess the
raw probe signal intensities, chips were scanned using the
GeneTitan® HTArray Plate Scanner (Affymetrix).
Microarray data analysis
Analysis of the microarray data was performed with the Bio-
conductor/R packages [6] (http://www.bioconductor.org).
The analysis was based on the Robust Multi-array
Average (RMA) expression levels of the probe sets,
computed with the package xps. Differential expression
was assessed via the moderated t-statistic implemented
in the limma package, described in [7]. To control the
false discovery rate, multiple testing correction was per-
formed [8] and probe sets with a corrected p-value
below 0.05 and an absolute fold change larger than two
were selected.
Molecular subtype discovery
Gene filtering
Intrinsically variable genes were first selected based on
their expression variation over the 118 PDAC samples
(2374 genes with s.d. > 0.8). The “PDAssign” genes were
selected as the variable genes matching the published
signature [5], i.e. 62 genes excluding 3 genes without
probes in our microarray platform (CELA3B, PRSS2,
SLC2A3) and 3 genes that are not variable (SLC16A1,
GPM6B, SLC5A3).
Identification of subclasses using non-negative matrix
factorization clustering
Subclasses of a data set consisting of unified expression
data of 118 samples and variable genes were computed
by reducing the dimensionality of the expression data
from thousands of genes to a few metagenes by applying
a consensus non-negative matrix factorization (NMF)
clustering method (v5) [9, 10]. This method computes
multiple k-factor factorization decompositions of the
expression matrix and evaluates the stability of the solu-
tions using a cophenetic coefficient. Consensus matrices
and sample correlation matrices were calculated for 2 to
5 potential subtypes (k) using default parameters and
Euclidian distance. The final subclasses were defined
based on the most stable k-factor decomposition and
visual inspection of sample-by-sample correlation matri-
ces. For this we used the NMF clustering implemented
from Gene Pattern software package [11].
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Merging microarray data using DWD
Distance Weighted Discrimination (DWD) method [12]
was applied for batch correction to the data of Collisson
et al. and our expression data on variable genes after row
median centering and column normalization according to
the authors’ protocol [5]. The Java version of DWD was
used with default parameters (Standardized DWD,
centered at zero).
Bioinformatic analysis
Gene Set Enrichment Analysis (GSEA) was used to score
how enriched the modules and regulons (identified
above in the first section) were in the top differentially
expressed genes for a given contrast [13]. We performed
the GSEA Preranked analysis using the list of the genes
ranked by the signed p-value from each of the super-
vised and unsupervised biological contrasts (e.g. PDAC
vs Control, k2.cl1 vs k2.cl2). This algorithm scores the
positive or negative enrichment for all modules/regulons
at the top or the bottom of the ranking. We also used
WebGestalt [14], in which the hyper-geometric test was
used for enrichment analysis and the Benjamini-
Hochberg procedure was used to control the False
Discovery Rate.
Top 250 KRAS dependency signature probes were ex-
tracted from Singh et al. [15] and provided a list of 187
genes, of which 165 genes were in our microarray data
and 77 genes showed variable expression (sd > 0.8). The
list of 77 genes was ranked according to their KRAS de-
pendency and was used to make an expression heatmap
of the 118 PDAC samples. Expression heatmaps are gen-
erated using R package heatmap. Hierarchical clustering
based on a Spearman rank correlation as distance metric
and an average linkage method (R function hclust) was
used predicting 112 samples (95 %) as KRAS dependent
samples (high level KRas activity) and 6 samples as
KRAS independent (low level KRAS activity). The R
function cutree automatically cut each dendrogram
(from the top down) to form two groups of samples.
KRAS expression levels are also significantly higher in
KRAS dependent samples compared to other samples
(p = 0.002).
Survival analysis
Kaplan-Meier estimates were used for survival analysis.
Overall survival (OS) was defined as time from surgery
to death, irrespective of cause. Disease-free survival
(DFS) was defined as time to tumor recurrence or death,
irrespective of cause. Patients were followed up until
death or until the date of study closure on November
2014. Together with the molecular subclasses the effect
on survival of a set of 16 clinico-pathological prognostic
factors was evaluated: patient age (years), gender (male/fe-
male), PDAC location (head/body or tail), tumor diameter
(mm), differentiation grade (pG), depth of tumor invasion
(pT), locoregional lymph node metastasis (pN), distant
organ metastasis (pM), completeness of tumor resection
(pR), magnitude of the surgical resection margin (pRM),
perineural invasion (PNI), vascular invasion (VI), lymph
vessel invasion (LVI), extra-capsular lymph node invasion
(ECLNI), AJCC TNM Classification 7th Edition, adjuvant
systemic chemotherapy (Yes/No). Log-rank tests and Cox
regression models were used to verify the relation between
a set of predictors and survival. A multivariable model
was constructed combining the predictors with p < 0.10 in
the univariable models, and p values less than 0.05 were
considered significant.
Master regulator analysis
In order to characterize regulatory networks underlying
the subtypes, we used iRegulon [16] to identify master
regulators, i.e. transcription factors whose regulons
(transcriptional target sets) are highly overlapping with
the observed gene signatures. The master regulators are
expected to be directly activated by signal transduction. In
this approach, we use a large collection of transcription
factor (TF) motifs (9713 motifs for 1191 TFs) and a large
collection of ChIP-seq tracks (1120 tracks for 246 TFs).
Briefly, this method relies on a ranking-and-recovery
strategy where the offline ranking aims at ranking 22284
genes of the human genome (hg19) scored by a motif
discovery step integrating multiple cues, including the
clustering of binding sites within cis-regulatory modules
(CRMs), the potential conservation of CRMs across 10
vertebrate genomes, and the potential distal location of
CRMs upstream or downstream of the transcription
start site (TSS+/−10 kb). The recovery step calculates
the TF enrichment for each set of genes, i.e. genes from
co-expression modules, leading to the prediction of the
TFs and their putative direct target genes in the module.
An important advance of this method is that it can
optimize the association of TFs to motifs using not only
direct annotations, but also predictions of TF orthologs
and motif similarity, allowing the discovery of more than
1191 TFs in human.
HNF1B immunohistochemistry
Samples (n = 6) showing top differential expression for
HNF1B were selected for HNF1B immunohistochemis-
try staining (IHC). Five-micrometer-thick sections were
prepared from formalin-fixed paraffin-embedded PDAC
specimens. Stainings were made using the Benchmark
Ultra (Ventana). Briefly, samples were deparaffinized at
72 °C and endogenous peroxidase activity was blocked
using 0.3 % H2O2. Antigens were retrieved by heating
the sections for 68 min at 91 °C in citrate buffer, pH6.
Sections were incubated with the primary antibody
against human HNF1B (Sigma, catalogue number
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HPA002083) dissolved 1:200 in Dako REAL antibody
diluent at 37 °C for 32 min. The reaction product was
developed using ultraView Universal DAB Detection Kit
and sections were counterstained with hematoxylin.
Sections were washed, dehydrated in progressively
increasing concentration of ethanol and xylene, and
mounted with xylene-based mounting medium. Normal
human pancreas was used as a positive control. In order
to check unspecific antibody binding, negative controls,
in which the primary antibody was omitted, were also
done. Samples were carefully analyzed by a pathologist.
Slides were visualized using Leica DMR microscope
(Leica Microsystems Ltd, Germany) and photographs
were taken using Leica Application Suite v3.5,0 software
(Leica Microsystems, Switzerland). HNF1B staining was
scored based on intensity (on a scale from 0–3; 0, nega-
tive; 1, weak; 2, positive; 3, strong) and the proportion of
reactive cells (0–100 %); histoscore was determined by
multiplying both parameters (range 0–300) as published
in Hoskins et al. [17]. When more than one magnifica-
tion area was available from a given tumor, the mean
score was used.
Results
Gene expression profiling
We applied gene expression profiling using microarrays
on 118 tumor and 13 histologically normal pancreatic
tissue samples (control) to investigate the molecular
mechanisms driving PDAC and its different subtypes.
Gene expression analysis of PDAC samples was
performed on whole tumor tissue, i.e. cancer cells (at
least 30 % of sample) and tumor stroma. Differential
gene expression analysis using the contrast of all PDAC
samples versus all control samples provided a large
number (n = 6873) of genes that were differentially
expressed (corrected p-value < 0.05; Additional file 1:
Table S1). Our findings are in agreement with previously
published pancreatic cancer gene expression data [18].
When we compared the gene expression profile of each
tumor sample against a published KRas dependent gene
signature [15], we found 94 % of our samples (112/118)
to be KRas-dependent, which is in agreement with the
fact that more than 90 % of PDAC have a KRAS driver
mutation (Additional file 2: Figure S1) [19, 20].
Molecular subtypes linked to survival
Recently, Collisson et al. studied gene expression profiles
of 27 microdissected PDAC samples, and identified three
molecular subtypes that are driven by the 62-gene PDAs-
sign signature, namely a classical, quasi-mesenchymal,
and exocrine-like subtype. These three subtypes were
found significantly linked to survival. The classical sub-
type was associated with the best survival, whereas the
quasi-mesenchymal subtype with the worst survival [5].
We used the PDAssign to classify our 118 PDAC
samples using NMF clustering, whereby the number of
clusters/subtypes (k) is a parameter. When k is set to 2,
3, 4, or 5, the analyses resulted in a stable clustering for
(all have cophenetic coefficient > 0.99) (Additional file 3:
Figure S2a). When we merged our data with those of
Collisson et al., we found almost a perfect match
(92.4 %) with their subtypes (Fig. 1). This finding cross-
validates the PDAssign signature on a large dataset of
whole-tumor samples with high-quality RNA.
We also confirmed the association of the classical sub-
type (k3.cl1) with the best survival (DFS and OS) as
compared to the other subtypes (Fig. 2). For the
exocrine-like (k3.cl2) subtype, Collisson et al. provided
an intermediate survival profile, though this was based
on survival data from 5 patients only. Our results from
50 exocrine-like subtype PDAC patients showed the
exocrine-like subtype to be associated with worse sur-
vival than the classical subtype, and comparable to that
of the quasi-mesenchymal (k3.cl3) subtype.
The results of the univariable and multivariable
models for OS and DFS are listed in Tables 1 and 2. Uni-
variable analyses identified several variables affecting
either OS or DFS. In multivariable analyses molecular
subtype k2 was the only independent predictor of both
OS (p = 0.031) and DFS (p = 0.034). Other independent
predictors of OS were molecular subtype k3 (p = 0.017)
and age (p = 0.008). In other words, we could use the
gene expression of the PDAssign signature to classify
new patient samples into one of three subtypes (using
k3), or one of two subtypes (using k2) and predict a link
to survival. Note that for k2, almost all the samples (92 %,
50/54) of the exocrine subtype remain as a separate group,
while the second cluster, k2.cl1, unites the classical and
QM subtypes together. These results suggest that molecu-
lar subtypes, but not clinicopathological factors, can be
used as independent predictors of survival.
Functional analysis of molecular subtypes
PDAC subtypes are poorly characterized at the molecular
level and little is known about the regulatory networks
underlying the expression of the genes driving better or
worse survival. As we could reproduce the three subtypes
(NMF with k = 3, or briefly “k3”) and confirmed their
prognostic relevance, we aimed to further characterize
their gene expression profiles, functions, and pathways.
Compared to normal tissue samples, all subtypes are
enriched for “Neoplasms”, “invasiveness”, and “integrin
family cell surface interactions”, and all subtypes are
comparably enriched for typical pancreatic cancer gene
signatures (FDR = 0.000, NES > =2.41).
When the k3 subtypes are compared directly against
each other (Additional file 1: Table S1), we could define
cluster-specific gene signatures as the genes that are
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specifically over- or under-expressed for a given subtype
and missing PDAssign genes were added to these signatures
to perform functional enrichment analysis (Additional file
4: Figure S3). For example, we found a specific gene signa-
ture with 148 genes over-expressed and 3 under-expressed
in the predicted exocrine-like subtype that is enriched for
processes related to the exocrine pancreas, such as pancre-
atic secretion and protease activity. For the QM subtype we
identified 50 up-regulated genes specific for this subtype
with 132 down-regulated genes, and this set of genes shows
typical properties of epithelial and mesenchymal cancers.
Focusing further on Epithelial-to-Mesenchymal Transition
(EMT) properties, we found an enrichment of an EMT sig-
nature (NES = 2.38). Some EMT TFs, such as TWIST1 and
SNAI2, show QM subtype specific expression. However, al-
though this signature resembles some aspects of EMT, it
does not capture the entire EMT signature, since there is
limited gene overlap with a core mesenchymal transition
signature derived by meta-analysis across cancer types [21].
Notice that samples clustered by low and high expression
of mesenchymal cancer attractors do not show a significant
link with survival. Finally, the predicted classical subtype
has very few specific genes compared to the other subtypes
(only 14 genes), and lacks any specific biological pathway
enrichment. Overall, despite a partial gene overlap with the
published PDAssign genes (36.4 %, 20/55) (Additional file 4:
Figure S3e), our larger cluster-specific gene signatures agree
with the known description of the PDAC subtypes.
Master regulators of PDAC
In the set of 2640 up-regulated genes in PDAC versus
Control, one of the most strongly enriched TF motifs
were those for IRF/STAT with a normalized enrichment
score (NES) of 4.89. We identified 1707 (64.5 %) of these
genes as targets of IRF/STAT (Fig. 3a-b). To identify the
most likely TFs that could bind to these motifs or target
genes, we compared the expression profile of all IRF and
STAT family members to the expression profile of the
predicted target genes, across the entire PDAC cohort.
Among all candidates, STAT1 and IRF9 showed the
highest correlation with the mean expression profile of
the specific predicted targets (Pearson correlation = 0.70
Fig. 1 Expression heatmap for merged data. a Heatmap for 56 PDAssign genes vs 184 PDAC samples (+13 histologically normal pancreatic tissue
samples as “Control” samples in grey). Samples are ordered and clustered by NMF clusters obtained from the NMF clustering of the merged PDAC
data. Genes are clustered by hierarchical clustering using Pearson correlation distance (complete linkage). Sample legends show the sample clustering
of the published subtypes (for the UCSF and GSE15471 tumors), but also the different predicted clusters from NMF of our 118 PDAC data (k3) and the
predicted K-Ras dependency (kras) (see also Additional file 2: Figure S1 and Additional file 3: Figure S2). b Comparison of the predicted subtypes and
known subtypes at the sample levels
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and 0.69, respectively; p-value < 2.2 × 10−16). Interest-
ingly, both TFs IRF9 and STAT1 physically interact and
cooperate in the same signaling pathways [22]. Note that
the IRF/STAT network is not differentially active be-
tween the PDA subtypes, but rather shows high expres-
sion across all PDAC samples, compared to normal
tissue samples (Additional file 5: Figure S4a-c). Several
additional motifs for relevant TFs were highly enriched
in the PDAC vs Control signature, such as motifs corre-
sponding to ETS-domain transcription factors (ETS1,
SPIB, SPI1 and PU.1) and AP-1 motifs (Fig. 3a).
We also found a ZEB1 motif (NES = 3.91) in the
regulatory analysis of 1325 down-regulated genes (Fig. 3c;
clustered with “LMO2” motifs) while ZEB1 is up-
regulated in PDAC samples (log ratio = 2.17, p-value =
2.32 × 10−21). This finding is consistent with ZEB1 being
a repressor [23]. Expression of ZEB1 has been shown re-
cently to be a strong predictor of survival in PDAC [24]
and is a known TF inducing epithelial-mesenchymal
transition (EMT) in cancer cells. Finally, we identified
enriched GATA3 ENCODE tracks in the “classical” and
“QM-PDA” specific gene signatures (NES ~ 4), but not
in the contrasts of PDAC vs control (data not shown).
Thus, besides the role of GATA6 in QM-PDA, as pro-
posed by Collison et al., our data also suggests that
GATA3 may be functional in the two other subtypes.
Within the set of 1325 down-regulated genes in
PDAC versus control, the most strongly enriched TF
motifs were those for HNF1A/B (NES = 5.036, Fig. 3c).
The HNF1A/B regulon, defined by 320 predicted tar-
get genes, is furthermore differentially expressed be-
tween classical and QM subtypes (Additional file 5:
Figure S4). HNF1A/B is also found as top enriched
regulator (NES = 8.156) when using a gene signature
specific for the classical subtype compared to the exo-
crine subtype (data not shown). Compared to HNF1A,
HNF1B is the best candidate to bind to this motif be-
cause the HNF1B gene itself is also down-regulated in
the tumor samples (log ratio = −1.34, p-value = 6.24 ×
10−5) and its expression profile is strongly correlated
with the predicted targets (Pearson correlation = 0.71,
p-value < 2.2 × 10−16), although HFN1A is also strongly
correlated with these genes (Pearson correlation =
0.52, p-value = 1.67 × 10−10).
Fig. 2 Disease-free (DFS) and overall survival (OS) of patients according to molecular subtypes of PDAC. Molecular subtypes are predicted by
using the published PDassign genes as a classifier of our PDAC samples. Survival according to 2 molecular subtypes (k2) classification: a DFS is
significantly better for k2.cl1 (red line) than that for k2.cl2 (blue line) (p = 0.035). b No statistically significant difference in OS is observed between
k2.cl1 (red line) vs. k2.cl2 (blue line) (p = 0.081). Survival according to 3 molecular subtypes (k3) classification: c DFS is significantly better for k3.cl1
(magenta line) than that for k3.cl2 (blue line) (p = 0.026). d No statistically significant difference in OS is observed between the 3 subtypes separately
(p = 0.193); k3.cl1 (magenta line), k3.cl2 (blue line), k3.cl3 (orange line). Tables 1 and 2 provide more information on these survival curves
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Table 1 Results of univariable and multivariable Cox regression models for disease-free survival (DFS)
Number
of Patients
Disease-free
Survival Time
(DFS; median
(CI): months)
Univariable Multivariable
Hazard ratio (HR) (95% CI) p-value Hazard ratio (HR)
(95% CI)
p-value
Clinicopathological Parameter
Age < 64 y. 58 10.2 (6.4 - 13.3) 0.756 (0.508 - 1.122) 0.165
> 64 y. 60 9.0 (7.3 - 10.9)
Gender Female 53 10.9 (8.1 - 13.5) 0.785 (0.528 - 1.161) 0.226
Male 65 7.8 (6.0 - 11.1)
PDAC Location Head 93 9.8 (7.4 - 12.4) 0.564 (0.357 - 0.921) 0.023 0.581 (0.340 - 1.015) 0.056
Body or Tail 25 8.3 (4.4 - 11.1)
Tumor diameter < 2 cm 27 13.1 (6.7 - 17.0) 0.676 (0.411 - 1.064) 0.092 0.739 (0.399 - 1.306) 0.306
> 2 cm 91 7.8 (3.3 - 18.9)
pG 1 10 13.1 (4.0 - 24.3) 0.715
2 41 10.2 (7.1 - 16.2)
3 67 7.7 (6.0 - 11.0)
pT 1 2 7.7 (7.3 - 8.1) 0.857
2 13 11.6 (7.1 - 17.1)
3 95 9.0 (6.8 - 11.4)
4 8 8.4 (7.4 - 11.2)
pN 0 45 10.3 (6.1 - 13.1) 0.839 (0.557 - 1.248) 0.39
1 73 8.8 (7.3 - 11.4)
pM 0 105 10.0 (7.7 - 12.3) 0.411 (0.230 - 0.802) 0.011 0.441 (0.097 - 1.458) 0.19
1 13 4.7 (3.2 - 10.9)
pR 0 91 10.0 (7.8 - 12.4) 0.712 (0.458 - 1.149) 0.159
1 27 7.7 (7.4 - 11.2)
pRM < 1 mm 64 10.0 (6.3 - 13.1) 0.925 (0.621 - 1.382) 0.7
> 1 mm 50 9.8 (7.0 - 12.3)
PNI 0 15 17.1 (3.3 - 56.1) 0.528 (0.264 - 0.955) 0.034 0.516 (0.233 - 1.053) 0.07
1 101 9.8 (7.4 - 11.4)
VI 0 36 11.1 (7.0 - 18.9) 0.629 (0.399 - 0.969) 0.035 0.805 (0.485 - 1.303) 0.382
1 76 8.0 (6.4 - 11.0)
LVI 0 34 10.2 (6.1 - 14.3) 0.833 (0.529 - 1.276) 0.408
1 81 8.8 (7.3 - 11.4)
ECLNI 0 69 10.4 (7.3 - 13.3) 0.821 (0.544 - 1.254) 0.356
1 43 8.4 (6.3 - 11.1)
AJCC TNM Stage 7th Ed. ≤ 2a 38 10.9 (6.8 - 14.3) 0.730 (0.474 - 1.100) 0.134
≥ 2b 80 8.5 (7.0 - 11.1)
N0 <T3 M0 (Early) 38 10.9 (6.8 - 14.3) Early vs Adv 0.498
(0.273 - 0.950)
Overall 0.104 Overall 0.209
N1 <T3 M0
(LNM)
62 9.8 (7.3 - 12.6) Early vs Adv
0.035
0.915 (0.295 - 4.022) 0.892
T4 or M1
(Advanced)
18 5 (3.3 - 10.4)
Adjuvant chemotherapy 0 36 7.4 (4.6 - 11.0) 1.139 (0.733 - 1.728) 0.553
1 82 10.0 (7.7 - 12.6)
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HNF1B protein expression in PDAC
As we identified HNF1B to be the strongest master
regulator (NES = 5.036), we studied the expression of
HNF1β on the protein level using immunohistochemis-
try (IHC) staining in normal and PDAC tumor samples.
HNF1β is known as a marker of prostate [25, 26] and
ovarian cancer [27, 28] but not of PDAC. HNF1B is also
involved in endocrine pancreas development and in
mesonephric duct formation [29]. IHC for HNF1β
showed a clear nuclear staining (Fig. 4). We observed
high expression levels of HNF1β in the acinar paren-
chyma (histoscore: mean ± SEM: 253, 7 ± 7, 8) and the
ductal cells of normal pancreatic tissue (histoscore: 256,
0 ± 8, 5), while the connective tissue was negative. In
premalignant lesions (high grade dysplasia), the expression
was lower compared to normal ducts (histoscore = 287.5).
A gradual loss of nuclear HNF1β expression was seen in
well differentiated towards moderately and poorly differ-
entiated tumors (histoscore: 102, 5 ± 2, 5 and 61, 8 ± 3,9)
compared to a non-neoplastic duct (histoscore: 264, 9 ±
12, 7). Additionally, we screened nine human PDAC cell
lines for the presence of HNF1B by IHC. We found, con-
sistent with the gene expression analysis, that most malign
pancreatic cell lines were negatives for HNF1B (Additional
file 1: Table S2). Only one cell line (non-metastatic clone
of SUIT2.028) was positive for HNF1B, while the highly
metastatic clone (SUIT2.007) stay negative. Therefore, a
loss or mutation of this gene might induce cancer. Since
HNF1B is highly expressed in normal pancreatic ductal
cells and loses its expression at that level in PDAC,
HNF1β might represent a key player in PDAC carcinogen-
esis and progression.
Discussion
In a recent attempt to unravel the tumor biology of pan-
creatic ductal adenocarcinoma (PDAC), Collisson et al. re-
ported the PDAssign gene signature to classify this lethal
cancer into three molecular subtypes with prognostic rele-
vance [5]. The association of PDAssign with survival was
based on gene expression data for 27 patients. In the
current study, we evaluated the validity of PDAssign in a
large cohort of 118 pancreatic cancer patients treated with
surgery with or without adjuvant systemic chemotherapy.
Apart from the sample sizes, another major difference
between these two studies is the fact that we used whole-
tumor samples including the micro-environment, whereas
the former study used microdissection to enrich their
samples for cancer cells. While microdissection of cells in
fixed tissue could possibly be associated with higher levels
of RNA degradation [30], we used high-quality samples
with a pathologically proven minimum of 30 % cancer
cells. By doing so, we kept the molecular information of
the microenvironment, we have reduced RNA contamin-
ation and the large number of samples improves the
signal-to-noise ratio. A future perspective may be to
decipher the tumour specific response using single cell
Table 1 Results of univariable and multivariable Cox regression models for disease-free survival (DFS) (Continued)
Molecular Subtypes
k2 Cluster 1 64 11.6 (7.4 - 16.2) 0.655 (0.440 - 0.976) 0.035 0.252 (0.092 - 0.888) 0.034
Cluster 2 54 7.8 (6.7 - 10.0)
k3 Cluster 1 42 13.5 (10.9 - 17.1) Cl1 vs Cl2 0.602
(0.382 - 0.940)
Overall 0.053 Overall 0.318
Cluster 2 50 8.0 (7.0 - 10.0) Cl1 vs Cl3 0.615
(0.363 - 1.066)
Cl1 vs Cl2
0.026
Cluster 3 26 4.7 (3.3 - 11.2) Cl1 vs Cl3
0.082
k4 Cluster 1 39 13.3 (9.8 - 16.7) Cl1 vs Cl2 0.670
(0.418 - 1.065)
Overall 0.333 Overall 0.751
Cluster 2 45 8.4 (6.7 - 10.0) Cl1 vs Cl2
0.090
Cluster 3 7 11.0 (4.8 - 17.1)
Cluster 4 27 4.7 (3.3 - 11.2)
k5 Cluster 1 41 13.5 (10.9 - 17.0) Cl1 vs Cl5 0.488
(0.251 - 1.021)
Overall 0.209 Overall 0.616
Cluster 2 35 8.4 (7.0 - 10.2) Cl1 vs Cl5
0.057
Cluster 3 4 9.3 (4.8 - NA)
Cluster 4 26 4.7 (3.3 - 11.2)
Cluster 5 12 7.5 (4.3 - 11.0)
Differences between variables or subgroups with a p-value of > 0.1 are not shown in the table and bold fonts indicate significant values (<0.05)
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Table 2 Results of univariable and multivariable Cox regression models for overall survival (OS)
Number of patients Overall survival
time (OS; median
(CI): months)
Univariable Multivariable
Hazard ratio
(HR) (95% CI)
p-value Hazard ratio
(HR) (95% CI)
p-value
Clinicopathological parameter
Age < 64 y. 58 23.5 (12.6 - 33.0) 0.626 (0.422 - 0.924) 0.018 0.551 (0.350 - 0.859) 0.008
> 64 y. 60 13.7 (11.4 - 16.8)
Gender Female 53 20.5 (12.9 - 29.3) 0.865 (0.587 - 1.269) 0.459
Male 65 12.6 (11.2 - 20.1)
PDAC location Head 93 19.5 (12.6 - 23.5) 0.600 (0.384 - 0.967) 0.036 0.714 (0.435 - 1.209) 0.204
Body or Tail 25 12.6 (10.0 - 26.4)
Tumor
diameter
< 2 cm 27 20.5 (11.7 - 36.5) 0.746 (0.459 - 1.165) 0.204
> 2 cm 91 14.8 (11.9 - 20.8)
pG 1 10 22.5 (1.5 - 33.2) 0.89
2 41 14.8 (11.2 - 29.3)
3 67 15.9 (11.5 - 23.5)
pT 1 2 13.4 (12.3 - 14.6) 0.694
2 13 26.9 (9.4 - 38.8)
3 95 15.9 (11.8 - 21.0)
4 8 12.4 (1.3 - 33.0)
pN 0 45 21.0 (14.6 - 29.3) 0.750 (0.499 - 1.111) 0.154
1 73 12.8 (11.7 - 17.8)
pM 0 105 17.8 (12.9 - 23.5) 0.569 (0.323 - 1.097) 0.089 0.624 (0.166 - 1.928) 0.427
1 13 11.4 (5.8 - 12.4)
pR 0 91 16.8 (12.9 - 25.6) 0.733 (0.474 - 1.174) 0.19
1 27 12.4 (7.0 - 23.4)
pRM < 1 mm 64 15.4 (11.8 - 25.6) 1.096 (0.737 - 1.622) 0.647
> 1 mm 50 16.7 (12.3 - 23.5)
PNI 0 15 37.8 (10.6 - NA) 0.468 (0.227 - 0.860) 0.013 0.561 (0.252 - 1.115) 0.103
1 101 15.9 (12.4 - 20.8)
VI 0 36 19.7 (11.9 - 33.2) 0.730 (0.466 - 1.115) 0.148
1 76 12.8 (11.5 - 23.4)
LVI 0 34 19.7 (10.6 - 33.0) 0.877 (0.561 - 1.334) 0.547
1 81 15 (12.3 - 21.7)
ECLNI 0 69 20.1 (12.9 - 30.5) 0.654 (0.437 - 0.987) 0.043 0.660 (0.398 - 1.089) 0.104
1 43 12.4 (10.2 - 20.8)
AJCC TNM
Stage 7th Ed.
≤ 2a 38 23.5 (16.8 - 31.7) 0.681 (0.443 - 1.023) 0.065 0.672 (0.166 - 2.254) 0.53
≥ 2b 80 12.6 (11.4 - 16.7)
Early (pN=0,pT≤ 3,pM=0) 38 23.5 (16.8 - 31.7) Early vs LNM 0.722
(0.463 - 1.106)
Overall 0.105
pN=1,pT≤ 3,pM=0 62 14.8 (11.2 - 21.7) LNM vs Adv 0.736
(0.425 - 1.328)
Early vs LNM
0.136
Advanced (pT=4 or pM=1) 18 11.7 (6.6 - 12.4) Early vs Adv 0.532
(0.295 - 0.997)
Early vs Adv
0.049
Adjuvant
chemotherapy
0 36 12.1 (7.0 - 16.8) 1.337 (0.874 - 2.002) 0.176
1 82 19.8 (13.9 - 25.6)
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Table 2 Results of univariable and multivariable Cox regression models for overall survival (OS) (Continued)
Molecular subtypes
k2 Cluster 1 64 20.9 (12.9 - 29.3) 0.710 (0.482 - 1.048) 0.081 0.247 (0.092 - 0.860) 0.031
Cluster 2 54 12.7 (11.2 - 16.7)
k3 Cluster 1 42 24.6 (16.8 - 33.2) Cl1 vs Cl2 0.680
(0.437 - 1.050)
Overall 0.193 Overall 0.017
Cluster 2 50 12.7 (11.2 - 16.7) Cl2 vs Cl3 1.055
(0.641 - 1.788)
Cl1 vs Cl2
0.082
Cluster 3 26 11.8 (6.6 - 20.5) Cl1 vs Cl3 0.717
(0.426 - 1.236)
Cl1 vs Cl3
0.226
Cl1 vs Cl3 0.209
(0.057 - 0.809)
0.024
k4 Cluster 1 39 23.5 (14.8 - 33.0) 0.577
Cluster 2 45 12.6 (10.6 - 16.7)
Cluster 3 7 26.2 (9.3 - 38.8)
Cluster 4 27 11.9 (6.6 - 21.0)
k5 Cluster 1 41 23.5 (14.8 - 33.2) Cl1 vs Cl5 0.398
(0.210 - 0.808)
Overall 0.122 Overall 0.271
Cluster 2 35 13.9 (11.4 - 21.7) Cl2 vs Cl5 0.483
(0.251 - 0.988)
Cl1 vs Cl5
0.012
Cluster 3 4 28.9 (9.3 - NA) Cl3 vs Cl5 0.298
(0.067 - 0.949)
Cl2 vs Cl5
0.046
Cluster 4 26 11.8 (6.6 - 20.5) Cl3 vs Cl5
0.040
Cluster 5 12 10 (6.9 - 16.6)
Differences between variables or subgroups with a p-value of > 0.1 are not shown in the table and bold fonts indicate significant values (<0.05)
Fig. 3 Master regulators in PDAC vs Control (histologically normal pancreatic tissue samples). a Result summary of the regulatory analysis with
iRegulon on 2640 up regulated genes. b Venn diagram of the predicted up-regulated targets from AP1, ETS and IRF. c Results of the regulatory
analysis with iRegulon on 1325 down-regulated genes. d Venn diagram of the predicted down-regulated targets from HNF1A/B and Nuclear
Receptors. Raw results of the analysis are presented in Additional file 4: Table S3 and Additional file 5: Figure S4
Janky et al. BMC Cancer  (2016) 16:632 Page 10 of 15
Fig. 4 (See legend on next page.)
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technology. Interestingly, a recent study shows that we
can defined stroma and tumour specific subtypes by ap-
plying a similar NMF approach on a compendium of
microarray expression data including 145 primary and 61
metastatic PDAC tumour samples [31]. They also identify
two stromal subtypes, normal and activated, with the
latter showing the worse prognosis. Nonetheless, we could
confirm PDAssign to be a reliable classifier of PDAC into
three distinct molecular subtypes with prognostic rele-
vance. With their approach, Moffit et al. [31] virtually dis-
sected the samples to identify a ‘classical’ and a ‘basal-like’
tumor-specific subtypes showing similarities to our pre-
dicted clusters with the ‘basal-like’ subtype showing genes
of the same family of the ‘quasi-mesenchymal’ subtype
with the worse survival. In our survival analysis, the clini-
copathological factors are not independent predictors of
survival, including stage and grade features. This is con-
sistent with the recent studies [5, 31] but not with the pre-
vious literature [32], which may be due to the larger size
of the recent studies. Moreover, we found these molecular
subtypes as independent predictors of both disease-free
and overall survival. We confirmed the classical PDAC
subtype to be associated with the best survival, though in
contrast to Collisson et al., we showed the exocrine-like
subtype to be associated with poor prognosis and compar-
able survival to that of the quasi-mesenchymal subtype.
We therefore envision that future evaluation of these mo-
lecular subtypes in larger studies may provide new insights
in novel treatment strategies, opening new perspectives in
personalized targeted therapy for PDAC.
In order to better understand the biology of PDAC we
used iRegulon to identify transcription factors as master
regulators of PDAC and its subtypes. We found that
HNF1A/B are among thousand TFs the top enriched
master regulators of the genes expressed in the normal
pancreatic tissue compared to the PDAC regulatory
network. On immunohistochemistry staining of PDAC
samples we confirmed low expression of HNF1B in well
differentiated tumors and no expression in six poorly
differentiated PDAC samples. Our IHC results are also
confirmed in an independent study from Jiang X et al.
[33], i.e. positive staining for HNF1β in acinar paren-
chyma and ducts from normal pancreas and negative or
moderate staining for PDAC samples. HNF1β also plays
an important role in human normal pancreas morpho-
genesis and terminal differentiation of pancreatic β-cells
[29]. Moreover, HNF1β is involved in regulating the β-
cell transcription factor network and is necessary for
glucose sensing or glycolytic signalling in the pancreatic
β-cells [34]. HNF1B was also found recently to be down-
regulated in vitro in PDAC cells by a microRNA mech-
anism involving hsa-miR-24 and/or hsa-miR-23a [35]. In
the suggested mechanism, HNF1B deregulation in
PDAC results in loss of the expression of the adhesion
molecule E-cadherin, which induces epithelial-mesenchymal
transition (EMT) and allows cells to detach from cell ag-
glomerations and to migrate. In another study [36], HNF1B
was also found deregulated in a mouse model of intraductal
papillary mucinous neoplasm (IPMN) to PDAC progression
with another duct-specific factor, SOX9, while the latter was
not found deregulated in our data and was not predicted in
our regulatory analysis. The authors highlighted the import-
ance of these factors for the loss of mature ductal identity in
tumor initiation. However, HNF1A has also been revealed as
a specific key regulator of the transcriptome in pancreatic
tumor tissues and was suggested as an important tumor
suppressor in the pancreas [17]. Hoskins et al. observed that
inducible over-expression of HNF1A in pancreatic tumor-
derived cells could generate growth inhibition, a G0/G1 cell
cycle arrest and apoptosis. Taken together, these observa-
tions suggest that HNF1A and HNF1B can be co-expressed
in normal pancreatic tissues and may act as tumor
suppressors through their regulatory activity. These
factors can dimerize as homo- or hetero-dimers and
can present several tissue-specific and species-specific
isoforms [37], which can explain why we can find their
activity independently. Low expression of HNF1B in
some PDAC samples could reflect the tumor origination
from acinar cells with incomplete ductal reprogramming
phenotype (as suggested by one of our peer reviewer). Add-
itionally, we identified IRF/STAT, AP-1, and ETS-family
members as key transcription factors in gene signatures
downstream of mutated KRAS. However, this approach
only captures a part of the regulatory network while the
post-transcriptional regulation and the microRNA regula-
tory network were not taken into account. We believe these
key TFs or master regulators represent a valuable set of
molecules for further study in functional assays and in vivo
(See figure on previous page.)
Fig. 4 Immunohistochemistry for HNF1β. a Strong nuclear expression in normal acinar parenchyma and normal ducts (upper part) while the
expression is completely lost in a poorly differentiated PDAC (lower part) (Magnification 50x). b IHC shows a lower expression in high-grade
dysplasia (upper part) compared to normal duct (arrow) (Magnification 100x). c IHC for HNF1β shows reduced expression in a well to moderately
differentiated PDAC compared to a non-neoplastic duct (asterisk) (Magnification 200x). Histograms showing the histoscores corresponding to the
left (a) (b) (c). Asterisk on the histogram indicates that the differences with each of the other categories are significant (Mann Whitney test,
p < = 0.0294). d Normal pancreas (positive control) showing a strong staining in ducts and in the acinar parenchyma (Magnification 40x)
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experiments to assess their role in PDAC carcinogenesis,
progression, and novel therapeutic strategies.
Conclusions
This is the first study describing in a large cohort of pancre-
atic cancer patients the prognostic relevance of molecular
subtypes, which are driven by the PDAssign gene signature.
Our results show molecular subtypes, but not clinicopatho-
logical factors, as independent predictors of survival. We
have identified enriched transcription factors (TFs) as
putative master regulators of PDAC, and their down-
stream networks, using iRegulon. Among them, the
hepatocyte nuclear factor 1 homeobox A/B (HNF1A or
HNF1B) and its predicted targets are globally down-
regulated in PDAC. Immunohistochemistry for HNF1B
shows a strong nuclear staining of normal pancreatic
ductal cells, whereas its expression is low in malignant
ductal cells of well differentiated and absent in poorly
differentiated PDAC samples. As these TFs play a key
role in PDAC, they may involve novel therapeutic
targets to improve the survival of patients with PDAC.
Additional files
Additional file 1:Supplementary Tables. Table S1. Differential
expression analysis performed by limma R package. Table S2. HNF1β
expression in different human pancreatic cancer cell lines. Table S3.
Master regulatory Results of gene set up-regulated in PDAC versus
Control. The results are based on the enrichment score of the motifs
(column 1), scores are the Area Under the Curve (AUC) and the Normalized
Enrichment Score (NES). Motifs clusters are shown in Cluster code column.
Predicted associated Transcription factors and predicted targets are shown
in the two last columns. The TF view display by iRegulon integrates the
results per clusterCode and prioritize the putative TF associated to a given
cluster of motifs. Table S4. Master regulatory Results of gene set down-
regulated in PDAC versus Control. See legend in Table S3. (XLSX 205 kb)
Additional file 2: Figure S1. KRAS-dependence analysis. (a) Expression
heatmap of the PDAC samples after hierarchical clustering of the samples
for the 77 variable genes that overlap with the set of top 250 K-Ras
dependence gene signature. The 6 samples predicted as KRAS
independent samples are in the left (blue clusters vs green clusters).
Genes are sorted according to the decreasing K-Ras dependence score.
Levels of expression of KRAS gene signature (b) and of KRAS gene (c) in
the different sample clusters. (d) Principal Component Analysis on the
expression profiles of KRAS gene signature allows to cluster the samples
into Control, KRAS dependent or KRAS independent samples (performed
with R packages prcomp and ggbiplot). (TIFF 1478 kb)
Additional file 3: Figure S2. Sample clustering using Non-negative
Matrix Factorization (NMF). (a) Clustering of 118 PDAC samples with k = 2
to 7 using the normalized expression profiles of 59 PDAssign genes. The
plot in the left shows the value of the cophenetic coefficient for different
k values (k = 2 to 7) indicating the stability of the sample clustering. When
we applied NMF clustering in an unsupervised approach (using all 2374
variable genes instead of the 56 PDAssign genes), the clustering of our
samples into two, four or five subtypes are predicted to be more stable
than three subtypes, although these are not associated with survival (b-c).
(b) Clustering of 118 PDAC samples with k = 2 to 5 using the normalized
expression profiles of variable genes (sd > 0.8). (c) Kaplan-Meier plots
showing Overall Survival for the NMF predicted clusters presented in
(b), i.e. molecular subtypes predicted by using the variable genes as a
classifier of our PDAC samples instead of the PDAssign genes as shown in
Fig. 2. Log Rank p-values are shown for the Disease Free Survival and
Overall Survival in each plot. (TIFF 554 kb)
Additional file 4: Figure S3. Subtype functional characterization. (a)
Venn diagram for differentially expressed genes for the predicted subtype
comparisons (limma, adjust.method = BH, padj.thr = 0.05, lfc.thr = 1).
Expression heatmaps of up- and down-regulated genes in Exocrine
subtype (b), QM-PDA subtype (c), and Classical subtype (d). Gene overlap
between PDAssign genes and only genes specifically up-regulated in our
predicted subtypes is shown in (e). Genes from the overlap are listed on
each heatmap (b, c, d). (EPS 12073 kb)
Additional file 5: Figure S4. Expression Levels of Master regulators and
their targets identified in PDAC vs Control. Expression levels by predicted
subtype of IRF predicted targets (a), IRF9 (b), STAT1 (c), HNF1B regulon
(d), HNF1B probes (e) and HNF1A probes (f). (TIFF 1117 kb)
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